Abstract: Immune checkpoint inhibitors (ICIs) have shown remarkable effect in the treatment of malignant tumor, which has opened a new era of tumor immunotherapy. However, with the wide application of ICIs, non-specific immune activation due to the drugs brought a series of immune-related adverse events (irAEs). Liver is a vital organ of drug metabolism and digestion. Therefore, immune-related hepatotoxicity should be concerned by clinicians. Early detection, early diagnosis, and standard treatment are the key points to improve the prognosis. Here, this review briefly described the incidence and possible mechanism of irAEs, and summarized the present management of immune-related hepatotoxicity.